Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2026)

Protalix BioTherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 84.94% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 84.94% YoY), while the FY2025 annual figure was $6.9 million, up 72.31% from the prior year.
• Operating Leases was $7.0 million for Q1 2026 at Protalix BioTherapeutics, up from $6.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $7.0 million in Q1 2026 to a low of $3.8 million in Q1 2025.
• Historically, Operating Leases has averaged $4.7 million across 5 years, with a median of $4.2 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Operating Leases fell 15.29% in 2025, then surged 84.94% in 2026.
• A 5-year view of Operating Leases shows it stood at $4.2 million in 2022, then rose by 10.84% to $4.6 million in 2023, then dropped by 12.88% to $4.0 million in 2024, then surged by 72.31% to $6.9 million in 2025, then grew by 1.6% to $7.0 million in 2026.
• The last three Operating Leases figures came in at $7.0 million (Q1 2026), $6.9 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.